New drug ARX517 targets advanced prostate cancer in early trial
NCT ID NCT04662580
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 22 times
Summary
This early-phase study tests a new drug called ARX517, alone or with other prostate cancer treatments, in 183 men with metastatic prostate cancer that has spread. The main goal is to check the drug's safety and find the right dose. Participants must have confirmed prostate cancer and, if not surgically castrated, must continue hormone therapy during the study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carolina Urologic Research Center
Myrtle Beach, South Carolina, 29572, United States
-
GU Research Network
Omaha, Nebraska, 68130, United States
-
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202-5116, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
UCSF Medical Center at Mission Bay
San Francisco, California, 94143-2350, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of California, Los Angeles School of Medicine
Los Angeles, California, 90095-3000, United States
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-5000, United States
-
University of Washington
Seattle, Washington, 98101, United States
-
Washington University St. Louis School Medicine Siteman Cancer Center
St Louis, Missouri, 63110, United States
-
Weill Cornell Medical College
New York, New York, 10021-5663, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.